Home › Neuroendocrine Tumors › California
Neuroendocrine Tumors clinical trials in California
14 studies for Neuroendocrine Tumors are looking for participants at sites in California.
Cities in California
- Los Angeles5 studies
- Mountain View5 studies
- San Francisco5 studies
- Baldwin Park4 studies
- Orange3 studies
- San Diego3 studies
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Cedars-Sinai Medical Center, Beverly Hills
- Norris Comprehensive Cancer Center, Los Angeles
- Stanford Cancer Center, Palo Alto
- and 2 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06943755Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- UCSF Benioff Children's Hospital, San Francisco
RecruitingPhase 1
24 Months – 18 Years · All sexes · Updated Sep 25, 2026 · NCT06441331Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
- Hoag Memorial Hospital Presbyterian, Newport Beach
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07087054Project: Every Child for Younger Patients With Cancer
- Kaiser Permanente Downey Medical Center, Downey
- City of Hope Comprehensive Cancer Center, Duarte
- Loma Linda University Medical Center, Loma Linda
- and 15 more
RecruitingObservational study
Up to age 25 · All sexes · Updated Aug 25, 2026 · NCT02402244A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Crinetics Study Site, Duarte
- Crinetics Study Site, Newport Beach
- Crinetics Study Site, Orange
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07129252CapTemY90 for Grade 2/3 NET Liver Metastases
- UC San Diego, La Jolla
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT04339036A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- St Joseph Heritage Healthcare, Santa Rosa
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT03093116Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
- Stanford University, Palo Alto
RecruitingPhase 1/2
Ages 20 to 99 · All sexes · Updated Apr 20, 2026 · NCT02174549Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
- Research Facility, Irvine
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Mar 30, 2026 · NCT05477576Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
- University of California, San Francisco, San Francisco
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 17, 2026 · NCT05746208Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
- City of Hope, Duarte
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
- Stanford Cancer Institute, Stanford
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Mar 17, 2026 · NCT04119024Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
- Cedars-Sinai Medical Center, Los Angeles
Recruiting
Ages 18 to 99 · All sexes · Updated Feb 20, 2026 · NCT04907643A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- University of Southern California, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Dec 11, 2025 · NCT06943521SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duarte
- Massive Bio SYNERGY-AI site, Irvine
- Massive Bio SYNERGY-AI site, La Jolla
- and 3 more
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.